ONO Pharmaceutical

ONO Pharmaceutical Co., Ltd. is a research and development-oriented pharmaceutical company focused on creating innovative medicines. The company's origins trace back to 1717 when Ichibei Ono launched his business in Osaka, Japan. The modern corporation, Ono Pharmaceutical Co., Ltd., was established on July 10, 1947.

The company's core business involves the discovery, development, manufacturing, and commercialization of pharmaceutical drugs. ONO Pharmaceutical specializes in areas with high unmet medical needs, particularly oncology, immunology, neurology, and specialty research. A key product in its portfolio is OPDIVO (nivolumab), an immune checkpoint inhibitor for treating various types of cancer, which was launched in 2014. This drug works by harnessing the body's own immune system to fight cancer cells.

ONO's business model is centered on intensive in-house research and strategic alliances with academic institutions and biotech companies globally. This collaborative approach allows the company to access external innovation and advance its pipeline. The company generates revenue through the sale of its pharmaceutical products to healthcare providers and institutions worldwide. ONO has a global presence, with subsidiaries and operations in Japan, the United States, Europe, and other parts of Asia.

Keywords: pharmaceutical, drug discovery, oncology, immunology, neurology, R&D, innovative medicines, cancer treatment, specialty pharma, clinical development